times more common in the group of icteric mothers, it must be emphasised that two perinatal deaths occurred in pregnancies associated with only maternal pruritus. Within the jaundiced group fetal outcome was not affected by the severity of the maternal biochemical disturbance or the gestational age at which symptoms began. In short, the individual fetus at risk is not identified by the indices currently used to gauge the severity of the maternal cholestasis.
times more common in the group of icteric mothers, it must be emphasised that two perinatal deaths occurred in pregnancies associated with only maternal pruritus. Within the jaundiced group fetal outcome was not affected by the severity of the maternal biochemical disturbance or the gestational age at which symptoms began. In short, the individual fetus at risk is not identified by the indices currently used to gauge the severity of the maternal cholestasis.
The cause of these sudden intrauterine deaths is not known. The birthweights of both the surviving and stillborn infants were normally distributed for their various maturities.8 Hence probably, unlike the chronic nutritional deficiency seen in intrauterine growth retardation, impaired placental perfusion or transfer is not a feature of this disorder. The consistent neocropsy evidence of intrauterine fetal hypoxia and the high associated incidence of intrapartum asphyxia do, however, suggest that some form of metabolic disturbance may occur.
The reason for the increased rate of premature births is also unexplained. In pregnancies complicated by maternal cholestasis Laatikainen et al"4 showed a change in fetal steroid synthesis. In particular, the fetus's liver has a reduced capacity to change 16-a-hydroxylate dehydroepiandosterone (DHAS) into the major precursor of the inert metabolite, oestriol. As a result, increased amounts of DHAS may reach the placenta and thus be metabolised through an alternative steroid pathway to the active hormone, oestradiol. In view of the recent implication of rising maternal plasma oestradiol 17-3 levels in the initiation of premature labour", it is tempting to postulate that the impairment of 16-oa-hydroxylase activity in pregnancies affected by cholestasis produces an "oestradiol surge" and consequent premature delivery.
The increased incidence of postpartum haemorrhage in these women is more easily explained. The hepatic synthesis of coagulation factors II, VII, IX, and X requires adequate tissue levels of vitamin K. As this is a fat soluble vitamin adequate absorption depends on the secretion of enough bile salts to promote mixedmicelle formation in the gut. Vitamin K deficiency may thus occur if maternal cholestasis is severe or prolonged. One of our patients was admitted from the antenatal clinic with generalised bruising together with greatly prolonged prothrombin and partial thromboplastin times. These values had been normal two weeks earlier and became so again within two days of parenteral vitamin K administration.
In view of the present inability to identify the individual fetus at risk of intrauterine death, we believe that pregnant women with cholestasis should be managed with watchful expectancy until 37 weeks' gestation. Then induction of labour should be considered. It The final mean daily dose of fludrocortisone was 0 2 mg (range 0-1 mg-0 4 mg). All four of the patients with initially reduced plasma albumin levels later developed the nephrotic syndrome and the fludrocortisone was reduced to prevent oedema. In three of these patients, all of whom have since died, fludrocortisone was subsequently stopped, and in the fourth patient (case 2) only a small dose, 01 mg every third day, was required. Serial blood analysis did not show any significant change in sodium or potassium values during treatment and except in the four patients with the nephrotic syndrome there were likewise no significant changes in the blood urea or plasma protein concentrations.
One patient (case 3) first developed symptoms of postural hypotension four weeks after treatment for pulmonary oedema complicating an acute myocardial infarction. She required no further diuretic treatment and has remained symptom-free on fludrocortisone. While on fludrocortisone treatment a second patient (case 11) developed pulmonary congestion and ankle oedema during pneumococal bronchopneumonia and on stopping the fludrocortisone temporarily there was no postural hypotension. Once the infection and pulmonary congestion were successfully treated the patient subsequently developed pronounced postural hypotensive symptoms and was restarted on fludrocortisone. A third patient (case 12) developed congestive cardiac failure secondary to ischaemic heart disease after six months on fludrocortisone and since then has required diuretic treatment; provided the patient has a trace of ankle oedema, she is free of symptoms of postural hypotension without fludrocortisone. Twelve patients had diabetic retinopathy (two background, six exudative, and four proliferative), and all had a blood urea of less than 6 6 mmol/l (40 mg/100 ml) before starting fludrocortisone. Of these 12 patients, five had proteinuria, four of whom (cases 1, 2, 10, and 14) had a reduced plasma albumin of less than 35 g/l. All 
Discussion
Postural hypotension in diabetes usually results from a disturbance of the complex vascular reflex control of blood pressure,' possibly with a decreased or absent renin secretion in response to the erect posture.8 It may be very distressing and in our experience the "symptomatic threshold" appears to be a fall in systolic blood pressure of 30 mm Hg on standing up, although we know of two normotensive male diabetics with a fall of 70 mm Hg associated with abnormal vascular reflexes but with no symptoms of faintness or dizziness. Patients need treating not only symptomatically to relieve faintness and dizziness but also because they may possibly die suddenly from brain stem anoxia. 9 Various methods have been suggested for treating postural hypotension, including physical measures such as abdominal binders, antigravity suits, and elastic tights, all of which are cumbersome and inconvenient for the patient, especially if the postural hypotension is associated with diabetic diarrhoea. In one study ephedrine was less effective than fludrocortisone,3 and the latter is considered to be the best drug for treating postural hypotension irrespective of cause.10 In our previous study of diabetics with postural hypotension fludrocortisone produced a considerable decrease in the postural fall of systolic blood pressure, a decrease in orthostatic tachycardia, and an increase in total plasma volume with no significant change in the plasma or urine osmolality.7
More prolonged therapeutic experience with fludrocortisone confirms the blood pressure findings in our previous study. The mineralcorticoid activity of fludrocortisone seems to have been responsible for the therapeutic effect and although we originally thought that hypertension might complicate the longterm use of fludrocortisone this has not been so.
The mean daily dose of fludrocortisone (0-2 mg) required for symptomatic relief is less than that required for controlling idiopathic postural hypotension, for which average doses are 0-5-2 mg/day.3 10-12 This variation in dosage may be explained by the different site of the lesion in idiopathic (very often an afferent or central lesion) and diabetic postural hypotension. In the latter the lesion is most probably efferent,7 affecting sympathetic peripheral vasoconstrictor fibres, and fludrocortisone, in addition to its mineralcorticoid activity, may produce some constriction in partially denervated blood vessels. '3 Although in our original study the fludrocortisone produced a rise in serum sodium and fall in serum potassium,7 these values remained within the normal range throughout the present longterm study. Proteinuria in a patient with postural hypotension should alert the clinician to use fludrocortisone with caution and the plasma albumin level should be carefully monitored-since any fall in the latter will potentiate the effect of the mineralocorticoid. The development of the nephrotic syndrome or of congestive cardiac failure, by producing fluid retention and secondary aldosteronism, has a "protective effect" in relieving the postural hypotension in autonomic neuropathy, although vascular reflexes such as the Valsalva manoeuvre and blood pressure response to sustained handgrip will still be abnormal."' Fludrocortisone may therefore have to be balanced with a diuretic to avoid serious postural hypotension or excessive fluid retention. Provided fludrocortisone is used with caution in these conditions, it is most useful for treating diabetics with troublesome postural hypotension.
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Forty-five patients with chronic renal failure (CRF) were studied. Fourteen patients were treated conservatively (group 1) and others with more advanced CRF were treated as follows: 15 patients who had not undergone nephrectomy were on haemodialysis (group 2); eight patients who had undergone bilateral nephrectomy were on haemodialysis (group 3); and eight patients who had undergone renal transplantation from two to 31 months previously and in whom the serum creatinine was below 177 jLmol/l (2 mg/100 ml) were taking prednisone 10-40 mg/day and azathioprine 150 mg/day (group 4).
Blood was taken from each patient (immediately before dialysis in those so treated) and plasma immunoreactive ,3-MSH was measured by a modification of the method of Thody and Plummer.3 In one patient blood was taken on two occasions from the arterial line at the start of haemodialysis, from the aterial and venous lines after three hours of dialysis, and from the arterial line at the end of dialysis. On the first occasion an Ultraflo 2 coil with Cuprophan was used and on the second a Rhone Poulenc RP6 dialyser with high permeability acronytrile membrane linked to a closed circuit monitor. In a second patient blood was taken before haemodialysis (using the Ultraflo 2 coil), during dialysis, and after dialysis.
Urinary immunoreactive (3-MSH was measured in one normal subject and in four patients with Nelson's syndrome. A 100-ml sample of freshly passed urine was first concentrated by freeze drying. The residue was dissolved in 10 ml of diluent buffer, which was acidified to pH 4 and the 3-MSH extracted by adsorption on to the silicate Spherosil, The 3-MSH was eluted from the Spherosil by a solution of equal parts of ammonia and ethanol; this solution was evaporated off and the 3-MSH assayed as for the plasma. With this method the recovery of added synthetic human 3-MSH to 100 ml urine was up to 40%.
Results
In patients with chronic renal failure not yet requiring treatment by dialysis there was a correlation between the degree of renal impairment as measured by serum creatinine levels and the plasma levels of ,-MSH (fig 1) .
Of the patients maintained on haemodialysis those who had undergone bilateral nephrectomy had significantly higher levels of rl-MSH than those who had not (fig 2) . The mean value (± SE) for patients with kidneys was 249 i 46 ng/l, which was significantly less than the mean value of 558 ± 69 ng/l after nephrectomy (P<0 001). This difference did not relate to the duration of dialysis, as the mean
